Catalyst Brief

← Calendar

Readoutin 45d

MoonLake Immunotherapeutics AG — Sonelokimab

Phase 3 primary completion: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response.

Date
Jan 2027
Type
Readout
Indication
Arthritis, Psoriatic

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.